StockData
Natera, Inc. logo

Natera, Inc.

NTRANasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 10/30234% above fair value
$378.92−35.38 (-8.54%)

Close on Nov 2, 2026Market cap $54.62BP/E –Yield –

Natera Qiagen Licensing Remaining Performance Obligations by Quarter

Qiagen Licensing Remaining Performance Obligations — RPO ($M) [legacy through Q3 2019] ($M)

Natera Qiagen Licensing Remaining Performance Obligations: $40M in Q3 2019, unchanged from a year earlier. No newer figure appears in the documents we track.

Latest, Q3 2019
40
Period ended Sep 30, 2019
Change on a year earlier
0.0%
40 in Q3 2018
History
7 quarters
Since Q1 2018
Sources
7
Documents cited below

Where the Q3 2019 figure comes from

Source: Form 10-Q (2019-11-08) ↗

Reported in Form 10-K/10-Q Note — Qiagen Collaboration (2018–2019Q3).

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedQiagen Licensing Remaining Performance Obligations — RPO ($M) [legacy through Q3 2019] ($M)Year on yearSource
Q3 2019Sep 30, 2019400.0%Form 10-Q (2019-11-08) ↗
Q2 2019Jun 30, 2019400.0%Form 10-Q (2019-08-09) ↗
Q1 2019Mar 31, 2019400.0%Form 10-Q (2019-05-10) ↗
Q4 2018Dec 31, 201840–Form 10-Q (2022-11-09) ↗
Q3 2018Sep 30, 201840–Form 10-Q (2018-11-09) ↗
Q2 2018Jun 30, 201840–Form 10-Q (2018-08-09) ↗
Q1 2018Mar 31, 201840–Form 10-K (2020-03-02) ↗

Cite this data

StockData. (2026). Natera Qiagen Licensing Remaining Performance Obligations ($M), quarterly Q1 2018–Q3 2019 [Data set]. Compiled from Natera SEC filings and investor materials. https://stockdatahq.com/stocks/ntra/kpis/rpo-qiagen-total

See every metric in the Natera KPI table. Data updated Nov 2, 2026.